同心医疗完成超亿美元战略融资，铸心基金、高榕创投、高科新浚联合领投

Core Insights - Tongxin Medical has successfully completed a strategic financing round exceeding 100 million USD, indicating strong market recognition of its strategic direction and global potential [1] - The funds raised will be primarily used to accelerate international expansion, continue product innovation, and enhance the domestic commercialization system [1] Company Overview - Founded in 2008, Tongxin Medical focuses on original innovation and technological breakthroughs, having developed China's first implantable ventricular assist device (CH-VAD) with complete independent intellectual property rights [1] - The CH-VAD was first implanted in a human by Academician Hu Shengshou from the Chinese Academy of Medical Sciences in June 2017, marking a significant milestone in the clinical application of durable VADs in China [1] - In November 2021, CH-VAD became the first domestically developed ventricular assist device approved for market entry in China, initiating the "artificial heart era" for the treatment of advanced heart failure [1] Investment and Market Position - Beijing Mentougou Zhuxin Fund highlighted Tongxin Medical's representation of international leading standards in the artificial heart field and its pioneering role in high-end medical device research and development in China [2] - Gao Rong Venture Capital noted that Tongxin Medical has successfully commercialized its all-magnetic levitation ventricular assist device in China and has initiated large-scale clinical trials in the U.S. with Medicare coverage, marking a significant recognition of its R&D capabilities [2] - Gao Ke Xinjun emphasized that Tongxin Medical is a leading company in the ventricular assist device sector in China, showcasing global competitiveness through technological breakthroughs and respect for clinical data [2] Future Outlook - The founder of Tongxin Medical, Dr. Chen Chen, stated that the company is advancing its global strategy and achieving key milestones in U.S. clinical trials, demonstrating its competitiveness in the international mainstream market [2] - The company aims to continue expanding the application boundaries of ventricular assist devices and lead technological development in the field on a global scale [2]